CHILDHOPE - Chimaeric T-cells for the treatment of paediatric cancers (FP6-LIFESCIHEALTH) (2006-11-01 - 2010-10-31) (»add to infobox)

Raphaël ROUSSEAU, Ettore BIAGI, Gustav GAUDERNACK, Joel PLUMAS, Martin PULE, Claudia RÖSSIG, Marianne Christina NAAFS-WILSTRA, Laurence LAPÔTRE

CENTRE LEON BERARD (FR716 - Rhône) (France), FONDAZIONE MATILDE TETTAMANTI E MENOTTI DE MARCHI (ITC45 - Milano) (Italy), RIKSHOSPITALET - RADIUMHOSPITALET HF (NO011 - Oslo) (Norway), ETABLISSEMENT FRANCAIS DU SANG RHONE-ALPES (FR711 - Ain) (France), UNIVERSITY COLLEGE LONDON (UKI11 - Inner London - West) (Great Britain), WESTFAELISCHE WILHELMS - UNIVERSITAET MUENSTER (DEA33 - Münster, Kreisfreie Stadt) (Germany), INTERNATIONAL CONFEDERATION OF CHILDHOOD CANCER PARENT ORGANISATION (NL310 - Utrecht) (Netherlands), ACIES SAS (FR716 - Rhône) (France)

Leukaemias are the most common cancers affecting children while malignant lymphomas - including non-Hogkin lymphomas (NHL) - comes in third position after brain tumours. A significant number of children with leukaemia/ lymphomas still fail current therapies. The aim of CHILDHOPE project is to develop a safe and efficient adoptive immuno -therapy for children with advanced or refractory malignancies. CHILDHOPE particularly focuses on three paediatric tumours: acute B-lineage lymphoblastic leukaemia, non-Hodgkin B-lineage lymphoma and acute myeloid leukaemia. The CHILDHOPE project is a new approach in paediatric cancer treatment since it brings from bench to bedside (and back) an innovative technology as yet never applied in children with advanced or refractory haematopoietic malignancies. The CHILDHOPE translational research project will focus on: (i) improving and testing efficacy and the safety of anti- leukaemia/lymphoma chimaeric T-cells in relevant preclinical models in vitro and in vivo in mice, (ii) scaling-up this technology to numbers suitable for a clinical application in children with haematopoietic malignancies and (iii) based on biological material obtained from our preclinical models and from children treated with these genetically engineered T-cells, dissecting the interface between the host's tumour and immune cells and use this knowledge to understand the mechanisms of anti-tumour action, validate novel targets and diagnostic tools specific to children affected with leukaemia or lymphomas. The CHILDHOPE project is built on the excellence of a network of EU-based partners with a broad experience in the field of paediatric haematology and oncology, immunology and cell & gene therapies and integrates the international confederation of parents with children with cancer and an SME specialised in the project management.

PERSONS (8/8)

RELATED NAVIGATION AREA(S) (2/2)